NCT03009474

Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers

Clinical Trial to Assess the Pharmacokinetic Characteristics of CJ-30060 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: HK inno.N Corporation · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor 10mg in healthy male volunteers.

Detailed description

The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor 10mg in healthy male volunteers.

Conditions

• Hypertension
• Hyperlipidemias

Interventions

Type	Name	Description
DRUG	CJ-30060	Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
DRUG	Exforge tab 5/160mg, Crestor tab 10mg	Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg

Timeline

• Start date: 2015-02-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2017-01-04
• Last updated: 2017-01-04

Locations

1 site across 1 country: South Korea